Newborn and Infant Nursing Reviews
Volume 6, Issue 3 , Pages 151-157 , September 2006

Patent Ductus Arteriosus in the Premature Infant: A Clinical Dilemma

  • Melinda Markham, MD

      Affiliations

    • Corresponding Author InformationAddress correspondences to Melinda Markham, MD, Division of Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3333 Burnet Avenue, OH 45229, USA.

References 

  1. Wyllie J. Treatment of patent ductus arteriosus. Semin Neonatol. 2003;8:425–432
  2. Fraser CD. Aortopulmonary septal defects and patent ductus arteriosus. In:  Gay SM,  Gery L editor. Critical heart disease in infants and children. St. Louis (Mo): Mosby; 1995;p. 716–723
  3. Zahka KG, Patel CR. The cardiovascular system. In:  Fanaroff AA,  Martin RJ editor. Neonatal-perinatal medicine: diseases of the fetus and newborn. 7th ed.. St. Louis (Mo): Mosby; 2002;p. 1138–1139
  4. Rudolph AM. Distribution and regulation of blood flow in the fetal and neonatal lamb. Circ Res. 1985;57:811–821
  5. Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res. 1999;45:19–29
  6. Gentile R, Stevenson G, Dooley T, et al. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. J Pediatr. 1981;98:443–448
  7. Shimada S, Kasai T, Hoshi A, et al. Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int. 2003;45:255–262
  8. Evans N, Malcolm G, Osborn D, et al. Diagnosis of patent ductus arteriosus in preterm infants. NeoReviews. 2004;5:e86–e97
  9. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr. 2001;90:184–191
  10. Puddy VF, Amirmansour C, Williams AF, et al. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002;103:75–77
  11. Sanjeev S, Pettersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol. 2005;25:709–713
  12. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;CD000503
  13. Lee J, Rajadurai VS, Tan KW, et al. Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics. 2003;112:345–350
  14. Achanti B, Yeh TF, Pildes RS. Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus. Clin Invest Med. 1986;9:250–253
  15. Cotton RB, Haywood JL, Fitzgerald GA. Symptomatic patent ductus arteriosus following prophylactic indomethacin: a clinic and biochemical appraisal. Biol Neonate. 1991;60:273–282
  16. Fowlie PW. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2002;CD000174
  17. Young TE, Mangum B. Indomethacin. In: Neofax: a manual of drugs used in neonatal care. 18th ed.. Raleigh, NC: Acorn Publishing; 2005;p. 124–125
  18. Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983;102:895–906
  19. Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics. 2005;116:1361–1366
  20. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2004;CD003480
  21. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649–1657
  22. Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2003;CD003745
  23. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr. 1997;131:549–554
  24. Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr. 1999;135:733–738
  25. Van Overmeire B, Vanhagendoren S, Schepens PJ, et al. The influence of ibuprofen-lysine on unbound bilirubin plasma levels in preterm neonates. Pediatr Res. 2004;55:474A
  26. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2003;CD003481
  27. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;CD004213
  28. Gournay V, Savagner C, Thiriez G, et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet. 2002;359:1486–1488
  29. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86:289–293
  30. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005;30:121–132
  31. Heyman E, Morag I, Batash D, et al. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003;112:e354
  32. Koehne PS, Bein G, Alexi-Meskhishvili V, et al. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med. 2001;29:327–334
  33. Kimball TR, Ralston MA, Khoury P, et al. Effect of ligation of patent ductus arteriosus on left ventricular performance and its determinants in premature neonates. J Am Coll Cardiol. 1996;27:193–197
  34. Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics. 1999;104:1345–1350
  35. Rojas MA, Gonzalez A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126:605–610
  36. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344:1966–1972

PII: S1527-3369(06)00057-2

doi: 10.1053/j.nainr.2006.05.004

Newborn and Infant Nursing Reviews
Volume 6, Issue 3 , Pages 151-157 , September 2006

Article Tools